Yale University

Vion Pharmaceuticals, Inc.

Other

Kenneth Brooks Low

David Gordon Bermudes

John M Pawelek

Martina Ittensohn

The present invention is directed to mutantsp. having a genetically modified msbB gene in which the mutantis capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutantfor growth inhibition and/or reduction in volume of solid tumors.

Genetically modified tumor-targeted bacteria with reduced virulence

The present invention is directed to mutantsp. having a genetically modified msbB gene in which the mutantis capable of targeting solid tumors. The invention is also directed tosp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purl gene. The present invention further relates to the therapeutic use of the mutantfor growth inhibition and/or reduction in volume of solid tumors.

Methods for use of genetically modified tumor-targeted bacteria with reduced virulence

The present invention is directed to mutantsp. having a genetically modified msbB gene in which the mutantis capable of targeting solid tumors. The invention is also directed tosp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutantfor growth inhibition and/or reduction in volume of solid tumors.

The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium Salmonella spp., such as , the bacterium and the protozoan . In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in treatment of solid tumors.

Vectors for the diagnosis and treatment of solid tumors including melanoma

The invention is directed to mutant having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.

Genetically modified tumor-targeted bacteria with reduce virulence

The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.

The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium Salmonella spp., such as,the bacterium,and the protozoan,In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in treatment of solid tumors.

The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.

Growing community of inventors

Guilford, CT, United States of America

Kenneth Brooks Low